Thursday, December 2, 2021

Japanese company buys Madison’s Semba Biosciences

It was a new version of a system that Semba used primarily for research that then attracted investment from Toso. The system can process and refine biological products being developed into medicines.

The company focused on monoclonal antibodies, which have been tested as potential vaccines and cancer fighters.

Amid the pandemic, antibodies have been used to help treat COVID-19 with varying levels of success.

That’s because they can help activate the human body’s immune system by attaching to sick cells, Mirendorff said, adding that antibodies have shown great promise in fighting future infectious diseases amid the health crisis.

Read Also:  Powell: Fed on track for slower aid to economy later this year

A 2018 article in the New England Journal of Medicine also noted that monoclonal antibodies may be effective on that front.

Tosoh Bioscience is headquartered in King of Prussia, Pennsylvania. Its parent company, Tosoh Corp. is based in Tokyo, and includes over 100 companies from around the world.

According to a statement from Tosoh, the company generated $6.9 billion in sales during the 2021 fiscal year, which ended in March.

The firm makes products called “resins” that separate biological material — including monoclonal antibodies — from “contaminants,” Mirendorff said. Semba has used Toso’s resins since 2010, Mirendorff said.

Nation World News Desk
Nation World News is the fastest emerging news website covering all the latest news, world’s top stories, science news entertainment sports cricket’s latest discoveries, new technology gadgets, politics news, and more.
Latest news
Related news
- Advertisement -